AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of fatumumab 20mg SC Monthly in Treatment Naive, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.

Is this Study for You?

Let's Get Started!



Type of Study



Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Anna Shah,  MD

Anna Shah, MD

Study ID

Protocol Number: 21-4783

More information available at NCT05084638

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers